Copper-binding agent (investigational)
Tetrathiomolybdate
Tetrathiomolybdate is an oral copper-binding molecule studied in Wilson disease, and the app lists a half-life of 4 hours that none of the records read reports as a measured figure.1
Tetrathiomolybdate after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- Tetrathiomolybdate
- Symbol
- TTM
- Family
- Metabolic and mitochondrial peptides
- Parts
- 13
- References
- 9
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Tetrathiomolybdate (TTM) is an oral copper-binding molecule; Weiss and colleagues describe the bis-choline form, WTX101, as "an oral first-in-class copper-protein-binding molecule".1 The same bis-choline compound appears in the FOCUS registry entry under the names "Formerly named WTX101; Tiomolibdic acid; Tiomolibdate choline; Bis-choline tetrathiomolybdate", and the app also lists ammonium tetrathiomolybdate, ATN-224 and the abbreviation TTM.2 Ala and colleagues (Hepatology Communications, 2026) describe tiomolibdate choline as a molecule "in development for the treatment of WD" (Wilson disease).3 The app grades the evidence as moderate; the bis-choline trials described below were sponsored by Wilson Therapeutics or Alexion, and the 1990s to 2000s trial of the ammonium salt carries a US National Institutes of Health grant.1,2,4
How it works
Sources in this part
Weiss and colleagues state that the bis-choline form "reduces plasma non-ceruloplasmin-bound copper (NCC) by forming tripartite complexes with albumin and increasing biliary copper excretion".1 Ala and colleagues write that penicillamine and trientine "bind Cu in blood and promote urinary Cu excretion", which is the contrast the app's notes draw with tetrathiomolybdate.3 In their 9-patient study, plasma total copper and directly measured non-ceruloplasmin-bound copper "increased immediately, consistent with Cu mobilization into blood and formation of stable tripartite complexes of Cu, TMC, and albumin".3 The app's notes describe the compound as avoiding free-copper spikes; the directly measured non-ceruloplasmin-bound copper in that study rose, which the authors describe as consistent with copper mobilization into blood and formation of stable tripartite complexes.3 Kirk and colleagues (Journal of Hepatology, 2024) gave oral radiolabelled copper to 16 healthy volunteers and report that tetrathiomolybdate "reduced intestinal 64Cu uptake by 82% 15 hours after the oral 64Cu dose".5 Their conclusion adds: "While we did not show an increase in biliary excretion of 64Cu following TTM administration", and the authors note that in animal models of Wilson disease the compound has been shown to facilitate biliary copper excretion.5 The 2026 copper balance study reports instead that the reduction in copper balance was "attributed to increased fecal Cu excretion".3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 30%
- Typical dose
- 15–120 mg/day
- Route
- Oral
- Time to peak
- ~2 h
The app's figures are a half-life of about 4 hours, oral bioavailability of 30% and a time to peak of about 2 hours; the records read give no measured figure for any of the three.6
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~4 h | No half-life figure is reported in the records read; the dosing schedule of the 2006 trial was 20 mg three times a day with meals and 20 mg three times a day between meals, which is the kind of schedule the app's notes use to infer the figure4 |
| Bioavailability | 30% | No absolute bioavailability is reported; a healthy-adult crossover trial compared one 15 mg enteric-coated tablet with three 5 mg tablets, with mean peak total molybdenum of 173.10 and 174.27 ng/mL (48 participants)6 |
| Time to peak | ~2 h | No time to peak is reported in the records read; the registry results for that trial list peak concentration and area under the curve of plasma total molybdenum, measured up to 240 hours after the dose6 |
Plasma total molybdenum was used in these trials "as a surrogate measure for ALXN1840", so the concentrations are of molybdenum rather than of intact tetrathiomolybdate.6
Food and gastric acid
A second Alexion-sponsored crossover trial in 18 healthy volunteers (NCT05319912) gave 60 mg of enteric-coated tablets after an overnight fast or 30 minutes after a high-fat breakfast, and 60 mg of non-coated capsules after omeprazole.7 The registry posts mean peak total molybdenum of 376 ng/mL fasted (SD 98.0), 187 ng/mL fed (SD 118) and 442 ng/mL after omeprazole (SD 69.6), in 18, 17 and 18 participants.7 The posted geometric mean ratio comparing the fasted and fed treatments is 40.49% (90% CI 31.12 to 52.68), and the ratio comparing the fasted tablet with omeprazole plus capsule is 82.65% (90% CI 63.91 to 106.90).7 The omeprazole arm also changed the formulation (non-coated capsules rather than enteric-coated tablets), so the registry numbers do not isolate the effect of gastric acid.7 In the 2026 copper balance study, tiomolibdate choline "was administered orally after an overnight fast" in the research unit.3
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Brewer and colleagues, Archives of Neurology, 20064 | Randomised, double-blind, 2-arm comparison of ammonium tetrathiomolybdate with trientine, both with zinc4 | 48 patients with the neurologic presentation of Wilson disease (25 on tetrathiomolybdate, 23 on trientine)4 | Tetrathiomolybdate 20 mg three times a day with meals and 20 mg three times a day between meals, or trientine 500 mg twice a day, plus zinc 50 mg twice a day; 8 weeks4 | Neurologic deterioration in 1 of 25 on tetrathiomolybdate against 6 of 23 on trientine (P<.05); anemia and/or leukopenia in 3 and further transaminase elevations in 4 on tetrathiomolybdate, anemia in 1 on trientine; 4 trientine deaths during follow-up, 3 of them in patients who had shown initial neurologic deterioration4 |
| Weiss and colleagues, Lancet Gastroenterology and Hepatology, 20171 | Open-label, single-arm phase 2 at 11 hospitals; funded by Wilson Therapeutics AB1 | 28 adults with Wilson disease, untreated or with no more than 24 months of prior chelator or zinc treatment1 | Bis-choline tetrathiomolybdate starting at 15-60 mg/day by baseline non-ceruloplasmin-bound copper, then response-guided; up to 24 weeks1 | 20 of 28 (71%) met the success criteria; mean corrected non-ceruloplasmin-bound copper fell 72%; 22 (79%) completed; reversible aminotransferase or gamma-glutamyltransferase rises without increased bilirubin in 11 (39%) of 28 patients who received at least 30 mg/day1 |
| FOCUS, ClinicalTrials.gov NCT03403205, Alexion, terminated2 | Phase 3, randomised, rater-blinded, tiomolibdate choline against standard of care2 | 214 participants aged 12 years and older with Wilson disease, in two cohorts by prior treatment2 | 15 mg every other day up to 60 mg daily against trientine, penicillamine, zinc or a combination; 48 weeks2 | Registry: higher direct non-ceruloplasmin-bound copper exposure (AUEC) on ALXN1840 in both cohorts; 1 death among 104 and 1 among 33 on ALXN1840 in the 48-week period, none on standard of care2 |
| Kirk and colleagues, Journal of Hepatology, 20245 | Double-blind, randomised, placebo-controlled mechanism study with radiolabelled copper and PET imaging5 | 16 healthy volunteers; separately 4 patients with Wilson disease5 | 15 mg/day for 7 days (TTM or placebo in volunteers)5 | In healthy volunteers, intestinal 64Cu uptake reduced by 82% at 15 hours; in 4 patients with Wilson disease, gallbladder 64Cu activity was negligible before and after treatment (no increase in biliary excretion shown), 64Cu was retained in the blood and hepatic 64Cu activity was reduced at all time-points5 |
| Ala and colleagues, Hepatology Communications, 20263 | Open-label, single-arm phase 2 copper balance study; funded by Alexion and AstraZeneca Rare Disease3 | 9 adults with Wilson disease (8 treatment-experienced, 1 treatment-naive), 2 centres3 | 15 mg/day on days 1-28, planned rise to 30 mg/day on day 29; 39 days3 | Cumulative mean decrease in copper balance of -6.08 mg over 21 days; 22 treatment-emergent adverse events in 7 of 9, no serious events or deaths; 1 participant discontinued on day 4 and 3 had dose reductions for grade 1 or 2 ALT elevations; clinical outcome data not collected3 |
The two healthy-adult pharmacokinetic registry trials are described under pharmacokinetics above, and the searches also returned registry entries for tetrathiomolybdate in other conditions, including multiple myeloma, prostate cancer, psoriasis and idiopathic pulmonary fibrosis, whose results are not summarised here.
Deeper analysis: Brewer 2006, tetrathiomolybdate against trientine
Brewer and colleagues, from the University of Michigan and collaborating centres, published a randomised, double-blind, 2-arm comparison in Archives of Neurology in 2006, described as "a randomized, double-blind, controlled, 2-arm study of 48 patients with the neurologic presentation of Wilson disease".4 The patients were "primarily newly diagnosed" and "had not been treated longer than 4 weeks with an anticopper drug".4 Both arms also received zinc, so the comparison is tetrathiomolybdate plus zinc against trientine plus zinc: "All patients received 50 mg of zinc 2 times per day".4 Patients "were hospitalized for 8 weeks, with neurologic and speech function assessed weekly", and drug adverse events "were evaluated by blood cell counts and biochemical measures".4 The headline result: "Six of 23 patients in the trientine arm and 1 of 25 patients in the tetrathiomolybdate arm underwent neurologic deterioration", with the paper reporting the difference as statistically significant.4 The adverse events were not one-sided: "Three patients receiving tetrathiomolybdate had adverse effects of anemia and/or leukopenia, and 4 had further transaminase elevations", against "One patient receiving trientine had an adverse effect of anemia".4 Deaths during follow-up were reported in the trientine arm: "Four patients receiving trientine died during follow-up, 3 having shown initial neurologic deterioration".4 The authors conclude that "Tetrathiomolybdate is a better choice than trientine for preserving neurologic function in patients who present with neurologic disease".4 The PubMed record lists a National Center for Research Resources grant (M01 RR 00042) and the first author's university affiliation; it contains no limitations statement and no conflict-of-interest statement, and the full text of the paper was not available to read.4 The registry entry NCT00004339, which lists the 2006 paper among its references, describes a double-blind randomised trial of tetrathiomolybdate against trientine with "Count: 90" enrolment and "Overall Status: COMPLETED"; the sources read do not explain why the 90 differs from the 48 patients in the paper.8
Deeper analysis: Weiss 2017, bis-choline tetrathiomolybdate phase 2
Weiss and colleagues, whose listed affiliations include Heidelberg, Warsaw, Vienna and Yale, report an "open-label, phase 2 study at 11 hospitals in the USA and Europe" in the Lancet Gastroenterology and Hepatology in 2017.1 The funder was Wilson Therapeutics AB ("FUNDING: Wilson Therapeutics AB."), and four listed authors (Flint, Olsson, Plitz and Bjartmar) give Wilson Therapeutics AB, Stockholm, as their affiliation.1 Of 28 patients enrolled, 22 (79%) completed 24 weeks, and treatment success was met by 16 (57%) with normalised and 4 (14%) with at least a 25% fall in corrected non-ceruloplasmin-bound copper.1 Mean corrected non-ceruloplasmin-bound copper "was reduced by 72% from baseline to week 24", and "No cases of paradoxical drug-related neurological worsening were recorded".1 On liver and blood safety the paper reports reversible aminotransferase rises "without increased bilirubin" in "11 (39%) of 28 patients who received at least 30 mg/day".1 Serious adverse events numbered 11 in seven (25%) patients and included "elevated liver aminotransferases (two events in two patients, one with agranulocytosis)" and "decline in neurological functioning (one event, likely due to natural disease progression although causality could not be ruled out)".1 The serious events also included psychiatric disorders (six events in four patients) and gait disturbance (one event); the paper assessed those seven as unlikely to be related to the study drug and the remaining four events as possibly or probably related.1 The design had no comparison group, and the paper states that "Investigators, other hospital personnel, and patients were aware of the identity of the treatment".1 The PubMed record does not include a limitations statement; the authors' interpretation is that "In view of its once-daily dose and favourable safety profile, WTX101 could improve the treatment of patients with this debilitating condition."1
Deeper analysis: FOCUS, the phase 3 trial of ALXN1840
The sponsor of FOCUS (ClinicalTrials.gov NCT03403205) was Alexion Pharmaceuticals, Inc.; the registry gives the design as "A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older".2 The registry shows "Overall Status: TERMINATED" with the stated reason "Sponsor decision to terminate the program", a start date of 2018-02-22 and a primary completion date of 2023-06-30.2 Enrolment was 214; participants were randomised by cohort in a 2:1 ratio to ALXN1840 or standard of care, with cohort 2 made up of people "who are treatment-naïve or who have received SoC therapy for ≤ 28 days".2 The primary outcome was the "Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks".2 The posted least-squares means were 2.50 on ALXN1840 against 0.87 on standard of care in cohort 1 (difference 1.64, 95% CI 1.14 to 2.13) and 4.76 against 0.96 in cohort 2 (difference 3.79, 95% CI 2.65 to 4.94).2 Ala and colleagues describe this measure as showing "greater mobilization of Cu compared with the current standard of care", and call the trial "a completed 48-week phase 3 randomized, controlled trial of TMC in WD patients that successfully met its primary endpoint"; the registry status is terminated, and three of those authors (Robinson, Cittadine and Tuffy) are employees of Monopar Therapeutics, which the paper names beside tiomolibdate choline as "TMC; Monopar Therapeutics, Wilmette, IL".3 Safety in the 48-week primary period: serious adverse events affected 14 of 104 and 4 of 33 on ALXN1840 against 6 of 56 and 0 of 14 on standard of care (cohorts 1 and 2), and one death was recorded in each ALXN1840 cohort and none on standard of care.2 In the same registry, discontinuation for adverse events was recorded for 4 participants on ALXN1840 in cohort 1 and 1 in cohort 2 against none on standard of care, and the secondary change from baseline in UWDRS Part III total score at week 48 (lower scores indicating improvement) was -2.24 (SD 7.458) on ALXN1840 against -1.59 (SD 6.188) on standard of care in cohort 1 and -2.06 (SD 9.843) against 1.55 (SD 5.889) in cohort 2.2 The registry gives no stated limitations; the sources read do not give the reason behind the sponsor's decision beyond the registry line.2
Deeper analysis: Kirk 2024, copper uptake and excretion
Kirk and colleagues at Aarhus University Hospital report a double-blind randomised study in 16 healthy volunteers who received 15 mg/day of tetrathiomolybdate or placebo for seven days, then oral radiolabelled copper one hour after the final dose.5 Four patients with Wilson disease were followed with intravenous 64Cu for up to 68 hours before and after seven days of 15 mg/day.5 In patients, "gallbladder 64Cu activity was negligible before and after TTM", while TTM "effectively retained 64Cu in the blood", reduced hepatic activity at all time-points and reduced cerebral activity two hours after the intravenous dose.5 Two listed authors (Swenson and Quicquaro) are affiliated with "Alexion, AstraZeneca Rare Disease, Boston, MA, USA", and the keywords include ALXN1840; the PubMed record gives no funding statement or limitations section.5
Deeper analysis: Ala 2026, copper balance in 9 patients
Ala and colleagues report an open-label, single-arm phase 2 study run "at 2 centers in the United Kingdom and New Zealand between September 2020 and May 2022" for 39 days.3 Patients started on 15 mg/day with a planned rise to 30 mg/day on day 29; "Five participants had a dose increase to 30 mg/day as planned beginning day 29, and 3 participants had dose reductions to 15 mg every other day, due to grade 1 or 2 elevated ALT values".3 One participant from cohort 1 discontinued on day 4 for "a major protocol deviation", and only one participant was in the treatment-naive cohort.3 The headline result is "The cumulative mean decrease from baseline in Cu balance was -6.08 mg over 21 days", and the fecal copper output-to-intake ratio "increased by 49% from 0.31 (0.17) at baseline to 0.48 (0.14) during the whole study period".3 Safety: "A total of 22 treatment-emergent adverse events (TEAEs) were reported in 7/9 participants (77.8%); no serious adverse events or deaths were reported", and "Two participants (22.2%) experienced hepatic TEAEs (abnormal liver function test, transaminase increased) that resulted in dose reductions".3 The authors write that "Enrollment in the study was challenging due to the rarity of WD", that "it is not feasible to fully capture and measure all routes of Cu excretion beyond the typical feces and urine", and that "clinical outcome data were not collected".3 The study "was funded by Alexion and AstraZeneca Rare Disease", and three authors are employees of Monopar Therapeutics.3
Doses reported in studies and on labels
No US label for tetrathiomolybdate was returned by a DailyMed search on 16 November 2026, so the doses below come from trials only.3
| Source | Dose and route | People and comparator | Length |
|---|---|---|---|
| Brewer and colleagues 20064 | Tetrathiomolybdate 20 mg three times a day with meals and 20 mg three times a day between meals, by mouth, plus zinc 50 mg twice a day; comparator trientine 500 mg twice a day plus zinc4 | 48 patients, neurologic Wilson disease4 | 8 weeks4 |
| Weiss and colleagues 20171 | Bis-choline tetrathiomolybdate, starting 15-60 mg/day by baseline non-ceruloplasmin-bound copper, then response-guided; no comparator1 | 28 adults with Wilson disease1 | Up to 24 weeks1 |
| FOCUS, NCT034032052 | ALXN1840 in 15 mg tablets, from 15 mg every other day up to a titrated 60 mg daily; comparator trientine, penicillamine, zinc or a combination2 | 214 participants aged 12 and older with Wilson disease2 | 48 weeks2 |
| Ala and colleagues 20263 | 15 mg/day by mouth on days 1-28, planned 30 mg/day from day 29; 3 participants reduced to 15 mg every other day; no comparator3 | 9 adults with Wilson disease3 | 39 days3 |
Sources in this part
The app's range of 15 to 120 mg/day matches these sources at the low end (15 mg/day) and, at the high end, the six 20 mg doses a day of the 2006 trial, which add to 120 mg a day.4
Side effects reported
Sources in this part
In the 2006 trial, three patients on tetrathiomolybdate had "anemia and/or leukopenia" and four had "further transaminase elevations".4 In the 2017 phase 2 study, reversible aminotransferase rises "without increased bilirubin" occurred in 11 (39%) of 28 patients who received at least 30 mg/day, and one serious event of raised aminotransferases occurred "with agranulocytosis".1 In FOCUS, treatment-emergent adverse events were posted for 89 of 104 and 30 of 33 on ALXN1840 against 41 of 56 and 12 of 14 on standard of care, in cohorts 1 and 2.2 In the 2026 copper balance study, 22 treatment-emergent adverse events occurred in 7 of 9 participants, "20 (90.9%) were mild", and two participants had hepatic events that led to dose reductions.3 The authors of that study call the safety profile one in which administration "was generally well tolerated"; the app flags the compound as hepatotoxic.3
Bloodwork and markers
Sources in this part
The app lists ceruloplasmin, non-ceruloplasmin-bound copper, complete blood count and liver enzymes as markers to monitor.4
- Non-ceruloplasmin-bound copper was the primary measure in the 2017 phase 2 study, corrected for copper held in tetrathiomolybdate-copper-albumin complexes, and the directly measured form was the primary measure in FOCUS.1,2
- Ceruloplasmin-bound copper "remained stable throughout the treatment period" in the 2026 copper balance study, while plasma total copper and directly measured non-ceruloplasmin-bound copper rose.3
- Aminotransferases and bilirubin were reported together in the 2017 phase 2 study, in which the rises occurred "without increased bilirubin".1
Regulatory and anti-doping status
Sources in this part
A DailyMed search for "tetrathiomolybdate" returned no US labels on 16 November 2026, and the sources read include no EMA or TGA document for it.2 The FOCUS phase 3 entry shows "Overall Status: TERMINATED" with "Why Stopped: Sponsor decision to terminate the program".2 Ala and colleagues describe tiomolibdate choline in 2026 as "in development for the treatment of WD".3 The WADA 2026 Prohibited List text contains no entry for tetrathiomolybdate or molybdenum (searched for "molybd" and "thiomolyb").9 Its class S0, "NON-APPROVED SUBSTANCES", is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and covers any pharmacological substance not addressed by the other sections that has no approval by a governmental regulatory health authority, with "drugs under pre-clinical or clinical development" given as examples.9 The list does not say whether tetrathiomolybdate falls under S0, and the sources read give no WADA ruling on it.9
What is not known
- No measured half-life, absolute bioavailability or time to peak for tetrathiomolybdate was identified in the records read; the app's 4 hours, 30% and 2 hours are not matched by a source figure.6
- The human studies read in detail were in Wilson disease or in healthy adults (for example 16 healthy volunteers given 15 mg/day for seven days), the searches also returned registry entries in other conditions whose results were not read, and the records read include no controlled trial of tetrathiomolybdate for copper lowering in healthy people.5
- The randomised comparison of tetrathiomolybdate with trientine reported in the 2006 paper enrolled 48 patients and treated them for 8 weeks, while the registry entry NCT00004339 lists an enrolment of 90 and the sources read do not explain the difference.4,8
- How much of the effect of tetrathiomolybdate comes from blood complexes, reduced gut uptake or biliary excretion is not settled in the sources read: Kirk and colleagues did not show increased biliary excretion, Ala and colleagues attribute their copper balance fall to increased fecal copper excretion and write that a meaningful amount of copper in fecal output could be systemic in origin.5,3
Frequently asked questions
What is the half-life of tetrathiomolybdate?
Is tetrathiomolybdate FDA approved?
Is tetrathiomolybdate banned by WADA?
What is ALXN1840 or WTX101?
They are names for bis-choline tetrathiomolybdate: the FOCUS entry gives "Formerly named WTX101; Tiomolibdic acid; Tiomolibdate choline; Bis-choline tetrathiomolybdate".2
How does tetrathiomolybdate work?
Weiss and colleagues say it "reduces plasma non-ceruloplasmin-bound copper (NCC) by forming tripartite complexes with albumin and increasing biliary copper excretion".1 Kirk and colleagues reported intestinal copper uptake reduced by 82% in healthy volunteers; in four patients with Wilson disease, gallbladder 64Cu activity was negligible before and after tetrathiomolybdate, and the authors did not show an increase in biliary excretion.5
What did the trial of tetrathiomolybdate against trientine find?
In 48 patients with neurologic Wilson disease, 1 of 25 on tetrathiomolybdate and 6 of 23 on trientine had neurologic deterioration (Brewer and colleagues, 2006).4 Three patients on tetrathiomolybdate had anemia and/or leukopenia, 4 had further transaminase elevations, and four patients on trientine died during follow-up.4
What side effects of tetrathiomolybdate have been reported?
Trials report anemia and/or leukopenia, aminotransferase rises and, in one serious event in the 2017 phase 2 study, aminotransferase elevation "with agranulocytosis".4,1 In that study, reversible aminotransferase rises "without increased bilirubin" occurred in 11 (39%) of 28 patients who received at least 30 mg/day.1
Has tetrathiomolybdate been given to healthy people?
Yes: Kirk and colleagues gave 15 mg/day or placebo for seven days to 16 healthy volunteers, and Alexion registered single-dose pharmacokinetic trials in healthy adults.5,6 These studies examined copper uptake and drug concentrations; the records read include no controlled trial of copper lowering in healthy people.5
More in Metabolic and mitochondrial peptides
References
- Weiss KH, et al. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2017. PMID 28988934
- Alexion Pharmaceuticals, Inc. Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease. ClinicalTrials.gov NCT03403205. NCT03403205
- Ala A, et al. Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial. Hepatol Commun 2026. PMID 42155004
- Brewer GJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006. PMID 16606763
- Kirk FT, et al. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease. J Hepatol 2024. PMID 38081365
- Alexion Pharmaceuticals, Inc. Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults. ClinicalTrials.gov NCT05303324. NCT05303324
- Alexion Pharmaceuticals, Inc. A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults. ClinicalTrials.gov NCT05319912. NCT05319912
- National Center for Research Resources (NCRR). Study of Tetrathiomolybdate in Patients With Wilson Disease. ClinicalTrials.gov NCT00004339. NCT00004339
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list